Navigation Links
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
Date:6/30/2008

t), somnolence (7.7 percent vs. 6.7 percent) and dry mouth (2.6 percent vs. 5.3 percent). As indicated above, the reported rates of "injection site pain," "injection site burning" and "dry mouth" occurred more frequently in the placebo group.

Tezampanel is the first AMPA/kainate-type glutamate receptor antagonist to be studied in clinical trials for chronic pain, including migraine. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain and fibromyalgia, as well as muscle spasticity and rigidity, thrombosis and epilepsy.

Migraine is a debilitating neurological condition characterized by an intense and disabling episodic headache. According to the National Headache Foundation, nearly 30 million people in the United States suffer from migraines. More than 50 percent of migraine sufferers endure from one to four migraine attacks per month. In addition to headache pain, migraine attacks are frequently accompanied by photophobia, phonophobia, nausea and vomiting.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is cu
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
2. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
3. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
7. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
8. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
9. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
10. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
11. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and ... Koob , Ph.D., Chief Scientific Officer, will present at ... will present on Tuesday, October 7, 2014, at 5:00PM ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... in Glasgow,have devised a new method of attacking ... of Clinical Investigation* today,(Thursday). , A team of ... mice a chemical that caused cancer cells to ... they were,carrying. The chemical kick started a gene ...
... Development Plans - , ,OTTAWA, Canada – March ... specializing in developing,advanced products related to High Density ... of,the Phase I/II Clinical Trial of its lead ... of dyslipidemia and heart,disease. , ,Results showed, to ...
Cached Medicine Technology:Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 2Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 3Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Diet Doc understands ... intentions to lose weight and their dieting attempts could be ... foods. Including hormone diet treatments into their programs ... patients to see fast and effective weight loss results, it ... forming healthy habits to maintain their weight for the future. ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected as ... American Made Awards (MSAMAs), an annual competition in recognition ... fields of crafts, design, food and style. , ... the MSAMAs, which celebrates entrepreneurs and artisans who are ... and changing the way we shop, work and live,” ...
(Date:10/1/2014)... HILLS, CA (PRWEB) October 01, 2014 ... Reshad will speak to a group of dental specialists ... in the northern Spain city of Oviedo. Dr. Reshad ... prosthodontist and lecturer with clients on two continents, will ... complex and aesthetic full mouth reconstruction. , “These specialists ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... survey which has sought to understand sexual behaviors has ... sex //in the present day are baseless and monogamy ... this survey are published in The Lancet. ... showed that many had just a single recent sexual ...
... grown from umbilical cord blood stem cells for the first ... experiments for drug testing. ,According to the scientists, ... just the initial phase of generating segments that can be ... mature functioning form. ,Scientists from Newcastle University ...
... always been the tourism industry with the scenic beauty of ... ,The latest buzzword in Kerala is medical tourism ... combination of fun and well. ,Tourists like 50-year-old ... Kerala’s medical tourism. ,When Anderson came to Kerala ...
... reluctant to seek medical treatment to correct the malady, a ... men found erectile problems affected 50 percent of men over ... China Morning Post said. ,But Andrew Yip Wai-chun, ... Wah Group of Hospitals, who released details of the study, ...
... has identified a key enzyme responsible for triggering a ... to new study findings published online// this week in ... Virginia Commonwealth University, the Hospital for Special Surgery and ... stage for development of new strategies and target therapies ...
... from breast cancer but who may not have the main ... higher than average risk of developing the disease. ... the BRCA1 and BRCA2 faults, they may be three times ... age of 50 than other women. ,Professor ...
Cached Medicine News:Health News:Artificial Liver from Cord Blood Stem cells 2Health News:Kerala to Venture into Medical Tourism 2Health News:Key Signaling Switch Identified in Allergic Disease 2Health News:Breast Cancer linked to Gene Risk 2
... EUB-2000 is a compact system capable ... This unit features intuitive operation, high ... membrane style keyboard incorporates an alphanumeric ... mode changes, and toggle keys for ...
... advanced circuit designs optimized for efficiency and ... an engineering philosophy that directs the development ... at the same time, providing seamless integration ... is extraordinary performance in image quality and ...
... flexible, and fast, the HI VISION ... edge technologies with user-oriented operation for ... SONO MR package consists of advanced ... including HI COMPOUND multi-angle spatial compounding, ...
... The Pentax EG-3630U incorporates a 2.4mm ... It features an all electronic convex linear ... electronic beam focus for improved lateral resolution, ... deeper ultrasound imaging. The color & ...
Medicine Products: